GSK lightens portfolio, shrinks footprint

Share this article:
GSK lightens porfolio, shrinks footprint
GSK lightens porfolio, shrinks footprint

GlaxoSmithKline is selling thrombosis meds Arixtra and Fraxiparine to the Aspen Group, a longtime partner in GSK's ongoing effort to transfer drugs from its books to another entity. The company said in a statement Monday that the deal will include $1.3 million in cash and that it transfers global rights, with few exceptions, to the products and to a manufacturing site (the Notre Dame de Bondeville site) and “certain dedicated commercial employees.” GSK said in a statement that the deal “is a further example of GSK's commitment to increase focus on products with the most growth potential.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.